In the AD brain, expression of MAP2 (found primarily in dendrites and implicated in learning and memory) is decreased while MAP-tau levels remain normal [34], and MAP2 immuno-staining is negatively correlated with NFT levels [35]. This evidence concerns the gene MAP2 and Alzheimer disease.